Tetrazin 25 mg (Tablet)

Indications

• Treatment of chorea associated with Huntington's disease

Pharmacology

• Vesicular monoamine transporter-2 (VMAT-2) inhibitor

Dosage & Administration

• Can be taken with or without food
• Individualization of dose with careful weekly titration required
• Starting dose: 12.5 mg daily
• Maximum daily dose: 100 mg (for extensive and intermediate metabolizers)

Interaction

• Reduction in dose with strong CYP2D6 inhibitors
• At least 20 days should elapse after stopping reserpine before starting Tetrabenazine

Contraindications

• Actively suicidal or untreated depression
• Hepatic impairment
• Concurrent use of MAOIs, reserpine, deutetrabenazine, or valbenazine

Side Effects

• Common adverse reactions: Sedation, somnolence, fatigue, insomnia, depression, akathisia, anxiety, nausea
• Rare adverse reactions: Suicidal thoughts, neuroleptic malignant syndrome, pneumonia

Pregnancy & Lactation

• Limited data on developmental risk during pregnancy and presence in human milk

Precautions & Warnings

• Periodic re-evaluation of benefit vs. adverse effects
• Maximum daily dose not to exceed 50 mg
• Maximum single dose not to exceed 25 mg with strong CYP2D6 inhibitor
• Discontinue in case of Neuroleptic Malignant Syndrome
• May impair ability to drive or operate machinery
• Not recommended in combination with drugs that prolong QTc

Overdose Effects

• Signs and symptoms may include drowsiness, sweating, hypothermia

Therapeutic Class

• Atypical neuroleptic drugs

Storage Conditions

• Store in a cool, dry place; protect from light and moisture; keep out of reach of children

Related Brands

• Tetrazin 12.5 mg (Tablet) - beacon-pharmaceuticals-plc